Scaly

Breast Cancer Therapeutics Market is expected to generate a revenue of USD 53.72 Billion by 2030, Globally, at 8.3% CAGR: Verified Market Research®

Retrieved on: 
Thursday, January 19, 2023
Cell, Novartis, Teva Pharmaceuticals, GlaxoSmithKline, Therapy, Tissue, Parent, Neoplasm, Menopause, DNA, Eli Lilly and Company, Breast cancer, Breast, Risk, Skin, Malignancy, Projection, AstraZeneca, Woman, Amgen, Radiation, Roche Diagnostics, Research, Cancer, Pfizer, Geography, Scaly, Incidence, USD, Obesity, Pharmaceutical industry, Medical imaging, Merck

JERSEY CITY, N.J., Jan. 19, 2023 /PRNewswire/ -- Verified Market Research® recently published a report, "Breast Cancer Therapeutics Market" By Drug Class (HER2 Inhibitors, Mitotic Inhibitors), By Therapy (Chemotherapy, Radiation Therapy), and By Geography.

Key Points: 
  • Due to the rising incidence of the condition, especially in developed nations, which will fuel the expansion of the Breast Cancer Therapeutics Market, the Global Breast Cancer Therapeutics Market is anticipated to witness exceptional growth in the future years.
  • The "Global Breast Cancer Therapeutics Market" is mainly bifurcated into sub-segments which can provide classified data regarding the latest trends in the market.
  • The "Global Breast Cancer Therapeutics Market" study report will provide valuable insight with an emphasis on the global market.
  • Based on the research, Verified Market Research® has segmented the global Breast Cancer Therapeutics Market into Drug Class, Therapy, and Geography.

Aditxt Forms Adimune, Inc. as a Wholly Owned Subsidiary with a Focus on Immune Modulation Therapies and Appoints Dr. Friedrich Kapp, Former President of the Therapeutic Business Unit at Schering AG, as its Chairman and CEO

Retrieved on: 
Tuesday, January 3, 2023
Health, Diabetes, Health Technology, Clinical Trials, Pharmaceutical, Biotechnology, Acceleration, Scaly, GMP, Skin, Psoriasis, Immune tolerance, Inflammation, Schering AG, Itchy, Joint Medical Service (Germany), Patient, CTA, Degenerative disease, Small Business Saturday, Immune system, Pharmaceutical industry, Vaccine

The CTA application will request approval for Adimune™ to conduct the first-in-human study in psoriasis patients, beginning in the second half of 2023.

Key Points: 
  • The CTA application will request approval for Adimune™ to conduct the first-in-human study in psoriasis patients, beginning in the second half of 2023.
  • Joachim-Friedrich Kapp, M.D., Ph.D., a 30-year veteran of the pharmaceutical industry and former president of the Therapeutics Business Unit at the multinational pharmaceutical company Schering AG, will serve as CEO of Adimune™ and chairman of the board.
  • Among his responsibilities as CEO of Adimune™, Dr. Kapp will be tasked with leading and developing the ADI™ immune modulation technology toward clinical trials.
  • Adimune’s™ product aims to prevent immune attacks by restoring immune tolerance and addressing the root cause of inflammation in skin.

Quoin Pharmaceuticals Announces Dosing of First Patient in Clinical Trial in Netherton Syndrome

Retrieved on: 
Tuesday, December 13, 2022
Asthma, Scaly, Quality of life, Clinical trial, Itchy, Dermatitis, Food, FDA, Safety, Dehydration, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Epidermolysis bullosa, Skin, Hair, SPINK5, Infection, Risk, Netherton syndrome, Attention deficit hyperactivity disorder predominantly inattentive, Mutation, IND, Standard of care, Peeling skin syndrome, Patient, Pharmaceutical industry, Scleroderma, Netherton

ASHBURN, Va., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, announces that the first patient has been dosed in its ongoing clinical trial evaluating the safety and efficacy of QRX003 as a treatment for Netherton Syndrome.

Key Points: 
  • This second study, which has now been cleared by the FDA to initiate clinical testing, is an open-label, non-placebo controlled trial that will evaluate 10 Netherton patients over a twelve week period.
  • The dosing of our first patient and the clearance of our second study are big steps forward for Quoin and, hopefully, for the community in general.
  • Quoin Pharmaceuticals Ltd. is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases.
  • Netherton Syndrome is a rare and sometimes fatal skin disease for which there is no approved treatment, and no cure.

Global Omega-3 Product Market to Reach $4 Billion by 2028 - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 15, 2022
Fitness & Nutrition, Health, Prostate, Capsule, Life, Soybean, Scaly, Endangered Species Act of 1973, Health, Policy, Endangered species, Government, Degenerative disease, Allergy, Colon, Cardiac arrest, Suggestion, Rectum, Cancer, Immunity, Fish, Skin, Tablet, Common Fisheries Policy, Fishery, Dihydroxy-E,Z,E-PUFA, Common, Lung, Stomach, Growth, Rash, Infection, Risk, Dietary supplement, Death, WHO, COVID-19, Magnuson–Stevens Fishery Conservation and Management Act, World Health Organization, Patient, Application

The "Global Omega-3 Product Market Size, Segments, Outlook, and Revenue Forecast 2022-2028 by Product Type, Source, Application, and Region" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Omega-3 Product Market Size, Segments, Outlook, and Revenue Forecast 2022-2028 by Product Type, Source, Application, and Region" report has been added to ResearchAndMarkets.com's offering.
  • Moreover, allergies related to fish oil and complex extraction procedure is also restraining the Omega-3 Product Market growth.
  • Omega-3 has been proven beneficial in boosting immunity to help fight COVID-19 and has increased the growth of the omega-3 product market.
  • In addition, the report also covers market size and forecasts for the four regions in the Omega-3 Product Market.

Chewy Launches “Letters to Chewy Claus” to Grant Wishes and Bring Joy to Thousands of Pets Across the Country

Retrieved on: 
Wednesday, November 16, 2022
Women, Pets, Men, Specialty, Philanthropy, Family, Fund Raising, Consumer, Retail, Online Retail, Holiday, Brand, Parent, Behavior, Greater good, PETS, Food, Paper, Prescription, Magic, Multimedia, NYSE, Scaly, Love, Human, Letter, CHWY, Family, Toy, Chewy

Chewy, Inc. (Chewy) (NYSE: CHWY), a leading destination for pet parents and partners, is creating holiday magic for pets across the country this year by launching their Letters to Chewy Claus program.

Key Points: 
  • Chewy, Inc. (Chewy) (NYSE: CHWY), a leading destination for pet parents and partners, is creating holiday magic for pets across the country this year by launching their Letters to Chewy Claus program.
  • And even if pets could get their paws on pens and paper, they had nowhere to send their holiday lists.
  • Letters to Chewy Claus was created to grant big and small holiday wishes for pets.
  • Through Chewy Claus, we are hoping to spread joy while recognizing the most important gift that keeps on givingthe love and companionship of our pets.

$50,000 Donated to Patriot PAWS by Pet Supplies Plus and Natural Balance® in Honor of Veterans Day

Retrieved on: 
Monday, November 7, 2022
Scaly, Texas Department of Agriculture, Nature, Brain damage, Texas Department of Criminal Justice, Awareness, Autumn, Multimedia, Pet, Woman, History, Dog, Prescription, Disabled American Veterans, E-commerce, Friends, PETS, CEO, Food, Islamic Development Coordination Council, View, Pet Supplies Plus, Partnership, Working dog, Volunteering, Natural Balance Pet Foods, Program, Diathesis–stress model, Trapping, Fur clothing, Online shopping, Age-related mobility disability, Veteran

DALLAS, Nov. 7, 2022 /PRNewswire/ -- Pet Supplies Plus, the largest and most trusted pet retail franchise has once again joined forces with Natural Balance® to raise awareness about the profound impact Service Dogs have on America's servicemen and women. Pet Supplies Plus and Natural Balance continue their national partnership with a donation of $50,000 to Patriot PAWS Service Dogs, a non-profit that trains and provides Service Dogs for disabled Veterans, at no cost. Pet Supplies Plus hosted a check presentation at their location in Dallas, Texas on November 3rd.

Key Points: 
  • In honor of Veterans Day, any purchase of Natural Balance products made at a Pet Supplies Plus store through November 27 will support the $50,000 donation to Patriot PAWS Service Dogs.
  • Pet Supplies Plus and Natural Balance presented the check together to Patriot PAWS joined by Patriot PAWS' Founder & Executive Director, Lori Stevens, Development Coordinator, Marissa Pittman, Development Coordinator, Sarah Mathers and Patriot PAWS Service Dog, Pierce.
  • "We are incredibly grateful to our friends at Natural Balance and Pet Supplies Plus," said Patriot PAWS Founder Lori Stevens.
  • "Natural Balance is incredibly proud to once again partner with Pet Supplies Plus to support Patriot PAWS," said Darcy Hagan, Vice President of Sales of Natural Balance.

Lilly to begin rollout of Tempo® Personalized Diabetes Management Platform

Retrieved on: 
Monday, November 7, 2022
Well, Scaly, Infection, Chemistry, Company, Private Securities Litigation Reform Act, Exercise, Skin, Conditional sentence, Diet, Vitamin, Heart, Time, Multimedia, Heart failure, Obesity, Biotechnology, Form 10-K, Alzheimer's disease, FDA, Death, Thiazolidinedione, Needle, Population, Bluetooth, Use, Eli Lilly and Company, Physician, U.S. Securities and Exchange Commission, Lilly, Insulin, Medicine, Cancer, Health, Form, Diabetes, Liver, Association, Patient, Blue star, American Diabetes Association, Blood, Solution, Pharmaceutical industry, Dietary supplement, Medical device, Health insurance, Dexcom, Facebook

Heart failure.Taking diabetes pills called thiazolidinediones /thIE-uh-zOH-li-dEEn-dIE-OHns/ (TZDs) with BASAGLAR may cause heart failure in some people.

Key Points: 
  • Heart failure.Taking diabetes pills called thiazolidinediones /thIE-uh-zOH-li-dEEn-dIE-OHns/ (TZDs) with BASAGLAR may cause heart failure in some people.
  • about all of your medical conditions, including if you have heart failure or other heart, liver, or kidney problems.
  • Tempo, Tempo Smart Button, Tempo Pen, and the Tempo logo are registered trademarks, and TempoSmart, and Tempo Insights are trademarks of Eli Lilly and Company, its subsidiaries or affiliates.
  • The Tempo Rings (in whole or part) are the property of Eli Lilly and Company.

EPI Health, a Novan Company, and MC2 Therapeutics Announce Data from Survey Conducted by National Psoriasis Foundation Presented at 42nd Annual Fall Clinical Dermatology Conference®

Retrieved on: 
Friday, October 21, 2022
Cream, U.S. Securities and Exchange Commission, Risk, Therapy, Skin, Wake Forest School of Medicine, Vitamin D, NDA, Scaly, Cytokine, Health, Patient, Patient satisfaction, National Psoriasis Foundation, Respiratory tract, Research, Security (finance), Annual report, Cataract, SB206, Technology, Molluscum contagiosum, Private Securities Litigation Reform Act, PAD, Company, Marketing, Headache, Rosacea, Acquisition, Collaboration, Safety, GLOBE, Zinc flake coating, Forward-looking statement, Creativity, MC2, Itch, Failure, Acne, FDA, COVID-19, Autoimmunity, Pharmacy, Compliance, Glaucoma, Pharmaceutical industry, Medical device, Healthcare, Dermatology, Calcipotriol, Medicine, Novin, Psoriasis

The National Psoriasis Foundation-fielded survey was conducted to assess psoriasis patients topical treatment experience, expectations and preferences.

Key Points: 
  • The National Psoriasis Foundation-fielded survey was conducted to assess psoriasis patients topical treatment experience, expectations and preferences.
  • Most of the participants in the survey self-reported having moderate psoriasis (83.9%) and were using topical therapy at least once per week (76%).
  • The patients reported their most bothersome symptoms to be scaly appearance (78.8%), bleeding/oozing (60%), itch (55%), and flaking (37.4%).
  • Novan, Inc. is a medical dermatology company primarily focused on researching, developing, and commercializing innovative therapeutic products for skin diseases.

Quoin Pharmaceuticals Announces Plans to Initiate a Second Clinical Trial in Netherton Syndrome Patients

Retrieved on: 
Tuesday, October 18, 2022
Quality of life, LinkedIn, Peeling skin syndrome, Disease, SEC, IND, Infection, Epidermolysis bullosa, Attention deficit hyperactivity disorder predominantly inattentive, Scaly, Dehydration, NASDAQ, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Standard of care, Asthma, Itchy, Private Securities Litigation Reform Act, Netherton syndrome, Food, Hair, Trial of the century, Company, Mutation, Application, Safety, Skin, GLOBE, Clinical trial, Dermatitis, Forward-looking statement, FDA, SPINK5, Risk, Pharmaceutical industry, Scleroderma, Netherton

ASHBURN, Va., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the Company or Quoin), a specialty pharmaceutical company focused on rare and orphan diseases, announces that it is initiating a second clinical trial in Netherton Syndrome patients.

Key Points: 
  • ASHBURN, Va., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the Company or Quoin), a specialty pharmaceutical company focused on rare and orphan diseases, announces that it is initiating a second clinical trial in Netherton Syndrome patients.
  • Quoin CEO, Dr. Michael Myers, said, We are very pleased to announce our plan to initiate this second clinical study in Netherton patients under our open IND application.
  • We firmly believe that, if approved, QRX003 has the potential to become the standard of care for Netherton patients.
  • Quoin Pharmaceuticals Ltd. is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases.

Aditxt’s (Nasdaq: ADTX) Adimune™ Program Has Initiated the Manufacturing Process of Immunotherapeutic Drug Candidate, ADI™-100 in Preparation for Planned Psoriasis First-in-Human Trials

Retrieved on: 
Friday, October 21, 2022
Health, Diabetes, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Psoriasis, Allergy, U.S. Securities and Exchange Commission, Apoptosis, Growth, Autoimmune disease, Joint, GMP, Scaly, Degenerative disease, CAGR, Annual report, Patient, Depression, Program, Security (finance), Nasdaq, Precision medicine, Itchy, Small Business Saturday, Immune system, Company, Industry, Immune tolerance, Joint Medical Service (Germany), CEO, Diabetes, Skin, Forward-looking statement, Schering AG, Risk, Vaccine, Pharmaceutical industry

Pending regulatory approvals, these trials will be performed in autoimmune diseases, with psoriasis as the first indication to be studied.

Key Points: 
  • Pending regulatory approvals, these trials will be performed in autoimmune diseases, with psoriasis as the first indication to be studied.
  • Encouraging toxicology study results for ADI-100 earlier established the safety profile of the drug candidate in the treatment of autoimmune diseases.
  • Psoriasis, caused when the immune system attacks skin cells, triggers chronic production of itchy, inflamed, thick scaly skin patches that can be very painful.
  • Many of those suffering with psoriasis also have serious health conditions such as diabetes, heart disease and depression.